{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:54:49Z","timestamp":1792601689547,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijantimicag.2023.106939","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T02:03:08Z","timestamp":1690596188000},"page":"106939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-4812","authenticated-orcid":false,"given":"Yutong","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Kipiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Maranchick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-7060","authenticated-orcid":false,"given":"Lali","family":"Mikiashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketevan","family":"Barbakadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4484-6994","authenticated-orcid":false,"given":"Wael A.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-5175","authenticated-orcid":false,"given":"Mohammad H.","family":"Alshaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-4996","authenticated-orcid":false,"given":"Russell R.","family":"Kempker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106939_bib0001","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0002","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0003","doi-asserted-by":"crossref","first-page":"210149","DOI":"10.1183\/20734735.0149-2021","article-title":"New developments in tuberculosis diagnosis and treatment","volume":"18","author":"Gill","year":"2022","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0004","series-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0005","doi-asserted-by":"crossref","DOI":"10.5588\/ijtld.18.0423","article-title":"QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment","author":"Monedero-Recuero","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0006","series-title":"WHO operational handbook on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0007","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0008","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study","volume":"73","author":"Brust","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0009","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13063-022-06331-8","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0010","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","article-title":"Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens","volume":"71","author":"Kempker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0011","series-title":"World Health Organization. Introduction of bedaquiline for the treatment of multidrug-resistant tuberculosis at country level: implementation plan","year":"2016"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0012","series-title":"World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","year":"2014"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0013","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/jac\/dkaa550","article-title":"Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis","volume":"76","author":"Alghamdi","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0014","year":"2017"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0016","unstructured":"Team RC. R: a language and environment for statistical computing. 2013."},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0017","doi-asserted-by":"crossref","first-page":"1800537","DOI":"10.1183\/13993003.00537-2018","article-title":"TBnet; of the TBnet QTc survey. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study","volume":"52","author":"Guglielmetti","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0018","first-page":"53","article-title":"Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis","author":"Hafkin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0019","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5588\/ijtld.21.0403","article-title":"QT prolongation in the STREAM stage 1 trial","volume":"26","author":"Hughes","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0021","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cpt.2685","article-title":"Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens","volume":"112","author":"Tanneau","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0022","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/psp4.12722","article-title":"Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis","volume":"10","author":"Tanneau","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/dmd.113.056119","article-title":"Bedaquiline metabolism: enzymes and novel metabolites","volume":"42","author":"Liu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0025","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0026","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"Yoon","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0027","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0028","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2042098612454283","article-title":"Drug-induced QT interval prolongation: mechanisms and clinical management","volume":"3","author":"Nachimuthu","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/157488610789869247","article-title":"Mechanisms of drug induced QT interval prolongation","volume":"5","author":"Ponte","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0031","first-page":"52","article-title":"Clofazimine does not lead to significant QT interval prolongation: a multicentre study","author":"Zweijpfenning","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.tox.2006.09.002","article-title":"Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels","volume":"228","author":"Zunkler","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.ijantimicag.2023.106939_bib0033","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1185\/03007995.2013.840568","article-title":"QT interval prolongation and the risk of torsades de pointes: essentials for clinicians","volume":"29","author":"Trinkley","year":"2013","journal-title":"Curr Med Res Opin"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:46:11Z","timestamp":1760377571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0924857923002182"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106939","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106939"}}